Related Experiment Video
Updated: Sep 26, 2025

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India
Mohammed Wasiq1, Ravi K1, Aravind Gn1
1Bangalore Medical College and Research Institute, Bangalore.
Abstract:
The recent second wave of COVID-19 cases in India has been marked by an unexpected increase in cases of mucormycosis reported in the context of COVID illness. Herein we aim to identify risk factors that may explain the sudden surge of cases and help develop preventive strategies.
Material:
We performed a case-control study comparing cases diagnosed with CAM and those who had recovered from COVID-19 without developing mucormycosis (controls). Information on comorbidities, glycemic control, and practices related to COVID-19 treatment was recorded.
Observation:
100 patients of CAM (cases) and 150 patients of COVID-19 without mucormycosis (controls) were included in the study. The spectrum of involvement of CAM cases included rhino-sinus (n=98, 98%), rhino orbital (n=58, 58%), rhino-orbito-cerebral (n=29, 29%). In CAM group symptoms of mucormycosis began a mean of 13.46 days after onset of COVID-19. The mean age of the CAM study group was 51.16 years with 69 males (69%) and 31 females (31.0). The most frequent comorbidities seen in our study population was diabetes (n=113, 45.2%) and hypertension (n=54, 21.6%). Diabetes was significantly more frequent among cases than controls (89% vs 24%, p <0.001). 31% of patients in CAM case group showed a common practise of steam inhalation during covid illness. Most common symptom reported in CAM was related to the eye which included eye pain (58%), lid swelling (54%), eye swelling (47%). Sino-nasal symptoms were nasal discharge (25%), nasal stuffiness (21%), and epistaxis (4%). Other common symptoms were headache (51%) and facial pain (36%). On examination of nasal cavity, crusting and ulceration were present in 83% patients. Eye involvement was present in 60% of cases, of which 27% of cases had vision loss. For definitive diagnosis of CAM, Potassium hydroxide (KOH) mount was positive for aseptate hyphae in 31 patients (31%). Use of systemic steroids for the management of COVID-19, was more frequent in CAM case group than control group (n=70, 70%). The CAM case group showed mean Hba1c of 10.7 ± 2.45, mean Serum Iron levels was 49.01 ± 18.69, mean ferritin was 913.37, mean CRP was 131.56 and mean LDH was 428.70.
Conclusion:
Overzealous use of steroids, uncontrolled sugars and repeated steam inhalation provided a favourable environment for the growth of mucormycosis. Judicious use of steroids and stringent glycemic control are vital to preventing mucormycosis.
Insights
The study identified that uncontrolled diabetes, frequent steroid use, and steam inhalation during COVID-19 treatment significantly increased mucormycosis risk. Judicious steroid use and strict blood sugar control are crucial for preventing this fungal infection.
Area of Science:
- Infectious Diseases
- Ophthalmology
- Critical Care Medicine
Background:
- The second wave of COVID-19 in India saw a rise in mucormycosis cases among patients with COVID-19 illness.
- Mucormycosis, a serious fungal infection, poses a significant threat, particularly to immunocompromised individuals.
Purpose of the Study:
- To identify risk factors associated with the surge of mucormycosis (CAM) in COVID-19 patients.
- To inform preventive strategies for mucormycosis in the context of COVID-19 management.
Main Methods:
- A case-control study was conducted comparing 100 patients with CAM to 150 COVID-19 patients without mucormycosis.
- Data collected included comorbidities, glycemic control (HbA1c), COVID-19 treatment practices (steroid use, steam inhalation), and clinical presentation of CAM.
Main Results:
- Diabetes was a significantly more frequent comorbidity in CAM cases (89%) compared to controls (24%).
- Systemic steroid use during COVID-19 treatment was higher in the CAM group (70%) than in controls.
- Common symptoms included eye involvement (58% eye pain, 47% eye swelling) and sino-nasal symptoms; 27% of cases with eye involvement experienced vision loss.
Conclusions:
- Overuse of steroids, uncontrolled diabetes, and steam inhalation create a favorable environment for mucormycosis growth.
- Judicious use of steroids and stringent glycemic control are vital for preventing mucormycosis in COVID-19 patients.
Related Concept Videos
Fungal Group Zygomycota
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Fungal Phylum Microsporidia

